PuSH - Publikationsserver des Helmholtz Zentrums München

Marchais-Oberwinkler, S.* ; Xu, K.* ; Wetzel, M.* ; Perspicace, E.* ; Negri, M.* ; Odermatt, A.* ; Möller, G. ; Adamski, J. ; Hartmann, R.W.*

Structural optimization of 2,5-tiophene amides as highly potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of osteoporosis.

J. Med. Chem. 56, 167-181 (2013)
Verlagsversion PDF DOI
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Inhibition of 17β-HSD2 is an attractive mechanism for the treatment of osteoporosis. We report here the optimization of human 17β-HSD2 inhibitors in the 2,5-thiophene amide class by varying the size of the linker (n equals 0 and 2) between the amide moiety and the phenyl group. While none of the phenethylamides (n = 2) were active, most of the anilides (n = 0) turned out to moderately or strongly inhibit 17β-HSD2. The four most active compounds showed an IC(50) of around 60 nM and a very good selectivity toward 17β-HSD1, 17β-HSD4, 17β-HSD5, 11β-HSD1, 11β-HSD2 and the estrogen receptors α and β. The investigated compounds inhibited monkey 17β-HSD2 moderately, and one of them showed good inhibitory activity on mouse 17β-HSD2. SAR studies allowed a first characterization of the human 17β-HSD2 active site, which is predicted to be considerably larger than that of 17β-HSD1.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter 4,5-disubstituted Cis-pyrrolidinones ; Estrogen-dependent Diseases ; Bicyclic Substituted Hydroxyphenylmethanones ; Hormone Replacement Therapy ; Human Placental Microsomes ; Nonsteroidal Inhibitors ; Biological Evaluation ; Ii 17-beta-hydroxysteroid-dehydrogenase ; 17-beta-hsd2 Inhibitors ; Dehydrogenase-activity
ISSN (print) / ISBN 0022-2623
e-ISSN 1520-4804
Quellenangaben Band: 56, Heft: 1, Seiten: 167-181 Artikelnummer: , Supplement: ,
Verlag American Chemical Society (ACS)
Begutachtungsstatus Peer reviewed
Institut(e) Molekulare Endokrinologie und Metabolismus (MEM)